Alnylam Q3 2021 Earnings Report
Key Takeaways
Alnylam Pharmaceuticals reported a combined net product revenue of $167 million for ONPATTRO, GIVLAARI, and OXLUMO in Q3 2021. The company reiterated its 2021 financial guidance, expecting combined net product revenues of $640-$665 million.
Achieved $167 million in combined net product revenues for ONPATTRO, GIVLAARI, and OXLUMO in Q3 2021.
Reported positive topline 18-month results from the HELIOS-A Phase 3 study of Vutrisiran in hATTR Amyloidosis Patients with Polyneuropathy.
Completed enrollment ahead of schedule in the HELIOS-B Phase 3 Study of Vutrisiran in ATTR Amyloidosis Patients with Cardiomyopathy.
Reiterated 2021 financial guidance, including combined net product revenues of $640-$665 million.
Alnylam
Alnylam
Alnylam Revenue by Segment
Forward Guidance
Alnylam reiterated its 2021 financial guidance.
Positive Outlook
- Combined net product revenues for ONPATTRO, GIVLAARI and OXLUMO are expected to be between $640 million and $665 million.
- Net revenues from collaborations and royalties are expected to be between $150 million and $200 million.
- Full results from the ILLUMINATE-C Phase 3 study of lumasiran at the American Society of Nephrology (ASN) Kidney Week 2021, being held November 2-7, 2021 in San Diego, California.
- Additional clinical results from the Phase 1 study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension, at the American Heart Association (AHA) Scientific Sessions, being held November 13-15, 2021 in Boston, Massachusetts.
- Full 18-month endpoint and safety results from the HELIOS-A Phase 3 study of vutrisiran in early 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income